Literature DB >> 30615816

Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: A National Inpatient Sample Study.

Alvin Thalappillil1,2, Margaret V Ragni1,2, Diane M Comer3, Jonathan G Yabes3,4,5.   

Abstract

INTRODUCTION: Among haemophilic (H) men, hepatitis C virus (HCV) is the leading cause of liver disease and mortality, but demographics and risks of hepatocellular carcinoma (HCC) in H are not well known.
METHODS: Adult discharges in H and non-haemophilic (NH) men, with and without HCC were identified in the National Inpatient Sample (NIS) between 1998 and 2014, using ICD-9 codes. Analyses included NIS-provided discharge-level weights to reflect national estimates. Categorical variables were assessed by Rao-Scott chi-square and continuous variables by weighted simple linear regression. HCC predictors were determined by weighted multivariable logistic regression.
RESULTS: Of 18 098 H, 144 (0.79%) had HCC between 1998 and 2014. Adjusted rates of HCC increased 3.0-fold in H vs 1.7-fold in NH (P = 0.484). Among HCV+, HCC rates adjusted for HIV, increased 2.2-fold in H vs 1.7-fold in NH (P = 0.740), while among HIV+, HCC increased 1.4-fold in H vs 0.2-fold in NH (P = 0.448). Among those with HCC, H were older than NH (P < 0.001), Caucasian (P = 0.006), platelet transfusion recipients (P < 0.001), with greater comorbidity (P < 0.001) and mortality (P < 0.006). H with HCC also had greater rates of HCV and HIV (each P < 0.001), lower rates of alcoholism and hyperlipidemia (each P < 0.001), and similar rates of HBV (P = 0.866), smoking (P = 0.507) and obesity (P = 0.502). In multivariable logistic regression, HCV was a strong predictor for HCC in haemophilia, (OR: 15.42, 95% CI: 8.75-27.16). DISCUSSION: Haemophilic men have increasing rates of HCC, similar to men without haemophilia. HCV is the major predictor of HCC in haemophilia. Future trends in HCC will depend on the impact of newer HCV antiviral therapy.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV; haemophilia; hepatitis C; hepatocellular cancer; trends

Mesh:

Year:  2019        PMID: 30615816     DOI: 10.1111/hae.13668

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

Review 1.  Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Authors:  Jerry R Mendell; Samiah A Al-Zaidy; Louise R Rodino-Klapac; Kimberly Goodspeed; Steven J Gray; Christine N Kay; Sanford L Boye; Shannon E Boye; Lindsey A George; Stephanie Salabarria; Manuela Corti; Barry J Byrne; Jacques P Tremblay
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454

2.  Implementation of Microelimination Strategy in Eradication of Chronic Hepatitis C Infection in Patients with Hemophilia in the Northern region of Serbia: Is Eradication Possible?

Authors:  Maja Ružić; Natalija Rajić; Milotka Fabri; Ivana Urošević; Marina Dragičević Jojkić; Tomislav Preveden; Maria Pete; Nebojša Rajić
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-09-01       Impact factor: 2.576

3.  Clinico-epidemiological and sociodemographic profile of patients with hemophilia in the Brazilian Amazon: High prevalence of hepatitis C infection and its possible corrrelation with inhibitor development.

Authors:  Enzo Miranda Santos; Jean de Melo Silva; Anderson Nogueira Barbosa; Gemilson Soares Pontes
Journal:  Front Public Health       Date:  2022-09-08

Review 4.  Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management.

Authors:  Anastasia Spanoudaki; Nikolaos Papadopoulos; Eleni-Myrto Trifylli; Evangelos Koustas; Sofia Vasileiadi; Melanie Deutsch
Journal:  J Multidiscip Healthc       Date:  2022-10-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.